AI’s drug‑discovery hype meets reality: limited clinical impact, slower road ahead
Derek Lowe reviews the AI‑driven pharma boom and finds concrete evidence of clinical benefit still scarce. He warns that AI may eventually improve target selection and trial design, but progress will be incremental and costly, demanding tempered expectations from investors and scientists alike.